Grant Details
| Grant Number: | 5R01CA225647-03 Interpret this number |
| Primary Investigator: | Shih, Ya-Chen |
| Organization: | University Of Tx Md Anderson Can Ctr |
| Project Title: | Targeted Oral Anticancer Agents: Patterns of Indicated and Off-Label Use, the Associated Factors, and Economic Implications |
| Fiscal Year: | 2021 |
Abstract
PROJECT SUMMARY Targeted oral anticancer medications (TOAMs) have been the focus of oncology drug development in the past two decades. Although these novel agents contribute to survival improvement in several cancers and are convenient to administer, high drug prices have raised concerns on their affordability and possibly low treatment adherence driven by high out-of-pocket expenses. Current knowledge on the utilization and adherence of TOAMs is largely built upon studies of patients with chronic myelogenous leukemia. It remains unclear whether such knowledge is directly transferrable to other cancers, especially those with both oral and intravenous anticancer medications as viable treatment options. The specific aims of the study are: (1) to examine the utilization patterns of TOAMs as indicated vs. off-label use; (2) to estimate the impact of TOAM use on the overall costs of cancer care, costs of non-hormonal systemic therapies, as well as out-of-pocket payment; (3) to investigate the factors associated with the initiation of a TOAM and time to treatment initiation; and (4) to explore patterns of treatment switches and discontinuation and the associated factors among patients who started their systemic therapy with a TOAM. We will address our research questions using various cohorts of cancer patients extracted from three large claims databases: the SEER-Medicare, MarketScan, and Health Care Cost Institution data. We will conduct a series of studies to better understand the role of TOAMs in modern cancer care delivery by systematically studying the utilization pattern and economic impact of TOAMs as well as factors affecting the initiation and discontinuation of these novel therapies, paying special attention to financial factors for patients and providers. The findings from our study will inform patients, clinicians, and policy makers of the extent to which off-label prescription of TOAM is practiced in the real-world and the long-term economic impact of TOAM use, and provide critical information to guide reform or re-design of insurance policies to avoid creating financial disincentive to prescribe or use TOAM. Ultimately, the goal of our research is to improve the accessibility, affordability, effectiveness, and safety of TOAMs.
Publications
A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome.
Authors: Pan I.W. , Halperin D.M. , Kim B. , Yao J.C. , Shih Y.T. .
Source: PharmacoEconomics, 2021 11; 39(11), p. 1271-1297.
EPub date: 2021-08-11.
PMID: 34378163
Related Citations
Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market.
Authors: Shih Y.T. , Xu Y. , Zhao H. , Schrag D. , Yao J. .
Source: JNCI cancer spectrum, 2021 Aug; 5(4), p. pkab045.
EPub date: 2021-05-18.
PMID: 34350376
Related Citations
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials.
Authors: Huey R.W. , George G.C. , Phillips P. , White R. , Fu S. , Janku F. , Karp D.D. , Naing A. , Piha-Paul S. , Subbiah V. , et al. .
Source: The oncologist, 2021 07; 26(7), p. 588-596.
EPub date: 2021-04-21.
PMID: 33783054
Related Citations
Time to add screening for financial hardship as a quality measure?
Authors: Bradley C.J. , Yabroff K.R. , Zafar S.Y. , Shih Y.T. .
Source: CA: a cancer journal for clinicians, 2021 03; 71(2), p. 100-106.
EPub date: 2020-11-23.
PMID: 33226648
Related Citations
State of Physician and Pharmacist Oncology Workforce in the United States in 2019.
Authors: Shih Y.T. , Kim B. , Halpern M.T. .
Source: JCO oncology practice, 2021 01; 17(1), p. e1-e10.
EPub date: 2020-12-03.
PMID: 33270520
Related Citations
Understanding Financial Hardship Among Cancer Survivors in the United States: Strategies for Prevention and Mitigation.
Authors: Yabroff K.R. , Bradley C. , Shih Y.T. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020-02-01; 38(4), p. 292-301.
EPub date: 2019-12-05.
PMID: 31804869
Related Citations
Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II-An Updated Analysis of SEER-Medicare Data.
Authors: Shih Y.T. , Xu Y. , Chien C.R. , Kim B. , Shen Y. , Li L. , Geynisman D.M. .
Source: PharmacoEconomics, 2019 12; 37(12), p. 1495-1507.
PMID: 31286464
Related Citations
Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
Authors: Shih Y.T. , Cortes J.E. , Kantarjian H.M. .
Source: The Lancet. Haematology, 2019 Aug; 6(8), p. e398-e408.
EPub date: 2019-06-14.
PMID: 31208943
Related Citations